Efficacy and tolerance of cyclosporin a in the treatment of multiple sclerosis
Schluep, M.; Steck, A.J.; Despland, P.A.; Regli, F.; Ochsner, F.; Berrut, E.; Gauthier, G.
Schweizerische Rundschau für Medizin Praxis 80(24): 670-672
1991
ISSN/ISBN: 1013-2058 PMID: 2068440 Document Number: 374871
The use and tolerance of cyclosporine A (Cy A) and azathioprine (AZA) are compared as long-term immunosuppression treatment for multiple sclerosis. 38 patients with multiple sclerosis were randomized and received either Cy A (5 mg/kg/d) or AZA (2 mg/kg/d) during 24 months. These patients were assessed clinically and with different biological parameters. The Cy A blood level was controlled, and Cy A was well tolerated without side effects forcing to stop the treatment. However, its benefits were limited when the different clinical scores are compared.